Mallinckrodt's Abuse-Deterrent Oxycodone IR May Face Hurdle At US FDA Panel
Executive Summary
FDA finds no benefit in deterring intranasal abuse; final data not yet submitted to determine IV abuse deterrence.
You may also be interested in...
Keeping Track: FDA Clears Motegrity And Second Herceptin Biosimilar, But Rebuffs SpecGx's Oxycodone
The latest drug development news and highlights from our US FDA Performance Tracker.
Mallinckrodt's Abuse Deterrent Oxycodone IR Narrowly Wins US FDA Panel Backing
"Incremental" step forward is sufficient for product to be labeled as deterring abuse by nasal, but not intravenous route, advisory committee members conclude.
Gottlieb Renews Call For New Opioid Review Paradigm As Democrats Prepare For House Control
US FDA's controversial approval of Dsuvia may prompt incoming House Democrats to pay special attention to commissioner's remarks on how agency reviews opioids.